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Many mouse models of breast cancer have been developed
that closely replicate human breast cancer subtypes at the
genomic level. In order to develop vaccines that could
prevent a broad spectrum of breast cancer subtypes,
a combination of different spontaneous tumor models
are needed. Transgenic models are available that mimic
HER2+/luminal breast cancer (TgMMTV-Neu) and triple
negative/basal-like breast cancer (TgC3(I)-Tag). Heteroge-
neous tumor types, including ER+ breast cancers, can be
induced by treating mice with medroxyprogesterone
(MPA) and the carcinogen 7,12-dimethylbenz[a]anthra-
cene (DMBA). The potential disadvantage of using the
DMBA model to study vaccine efficacy is that DMBA has
been reported to be an immunotoxin, potentially affecting
the function of T, B, and antigen presenting cells. In order
to address the utility of the DMBA model for vaccine
studies, we performed experiments to look at the effect of
DMBA on the immunogenicity of breast cancer vaccines.
To assess immunity, three groups of FVB mice (n=8 each)
were injected with either (a) adjuvant only, (b) IGF-IR
peptide vaccine, or (c) IGF-IR peptide vaccine followed by
MPA/DMBA treatment. Seven days following the final
DMBA treatment (49 days post-vaccination) splenocytes
and sera were subject to immunological testing. IFNg
ELISPOT assays and ELISAs were performed to measure
IGF-IR peptide-specific T-cell and humoral immunity,
respectively. ELISPOT assays revealed that DMBA treat-
ment significantly reduced-T cell responses to the vaccine
peptides (22% compared to the vaccine-only group,
p=0.015), but had no significant effect on T cell responses
to the positive control mitogen ConA (p=0.52) or back-
ground activity (p=0.87). For the control, vaccinated and
vaccinated/DMBA groups, average spots/well with IGF-IR
peptides were 0.8 (±0.9), 38.7 (±27.4), and 8.6 (±6.3), and
with ConA were 352 (±30.5), 325( ±39.6), and 242 (±73.2),
respectively. Humoral immunity was not impaired in the
DMBA treated animals. Two IGF-IR peptides (p1212 and
p1302L) generated significant antibody responses in the
vaccinated and vaccinated/DMBA animals compared to
the control group (p=0.001 to 0.018), but there was no
significant difference between the vaccinated ±DMBA
groups (p=0.58 and 0.72). Mean IgG titers against p1212
were 0.07 (±0.08), 167 (±0.74), and 144 (±91) μg/ml,
and against p1302L were 0.02 (±0.04), 129 (±89), and
146 (±98) μg/ml for the control, vaccinated, and vacci-
nated/DMBA groups, respectively. Chemically induced
spontaneous tumor models are commonly used for studies
of lung, skin, and colon cancers. Data presented here
would suggest an evaluation of the carcinogens impact
on immunity should be undertaken prior to using such
models to evaluate immune therapeutics.
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